Melanin-concentrating hormone antagonist

A compound represented by the formula:

• 298
• wherein Ar1 is a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• Y is a spacer having a main chain of 1 to 6 atoms;
• ring A is benzene ring which may be further substituted;
• ring B1 is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted;
• and
• R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
• or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted;
• or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring (except piperidine) which may be substituted;
• provided that, when X is CO, ring B1 is not azepane or 4,5-dihydroazepine each of which may be further substituted, or Ar1 is not biphenylyl which may be substituted, and that Y is not —CO—(C(Ra)H)na— (Ra is hydrogen atom or a hydrocarbon group which may be substituted, na is an integer of 1 to 10) and does not have a bicyclic nitrogen-containing heterocyclic ring substituted with amino group;
• or a salt thereof.

A compound represented by the formula:

• 303
• wherein R is hydrogen atom, a halogen atom or a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• Ya is a spacer having a main chain of 1 to 5 atoms;
• ring A is benzene ring which may be further substituted;
• ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted;
• Z is CH or N;
• and
• Rb is hydrogen atom or a hydrocarbon group which may be substituted;
• provided that Ya does not have a bicyclic nitrogen-containing heterocyclic ring substituted with amino group;
• or a salt thereof.

A compound represented by the formula

• 308
• wherein R is hydrogen atom, a halogen atom or a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• ring A is benzene ring which may be further substituted;
• ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted;
• w7 is an integer of 0 to 4;
• and
• R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
• or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted;
• or a salt thereof.

A compound represented by the formula:

• 309
• wherein R is hydrogen atom, a halogen atom or a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• ring A is benzene ring which may be further substituted;
• ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic group which may be further substituted;
• w2 is an integer of 0 to 5;
• Z is CH or N;
• Rc is a hydrocarbon group which may be substituted;
• or a salt thereof.

A method for preventing or treating diseases caused by a melanin-concentrating hormone in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound represented by the formula:

• 310
• wherein R is hydrogen atom, a halogen atom or a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• Y is a spacer having a main chain of 1 to 6 atoms;
• ring A is benzene ring which may be further substituted;
• ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted;
• and
• R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
• or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted;
• or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted;
• or a salt thereof.

A method for preventing or treating obesity in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound represented by the formula:

• 311
• wherein R is hydrogen atom, a halogen atom or a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• Yb is a spacer having a main chain of 1 to 6 atoms;
• ring A is benzene ring which may be further substituted;
• ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted;
• and
• R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
• or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring (except piperidine) which may be substituted;
• or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted;
• provided that Yb is not —CO—(C(Ra)H)na— (Ra is hydrogen atom or a hydrocarbon group which may be substituted, na is an integer of 1 to 10);
• or a salt thereof.

Use of a compound represented by the formula:

• 312
• wherein R is hydrogen atom, a halogen atom or a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• Y is a spacer having a main chain of 1 to 6 atoms;
• ring A is benzene ring which may be further substituted;
• ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted;
• and
• R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
• or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted;
• or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted;
• or a salt thereof, for the manufacture of a pharmaceutical preparation for preventing or treating diseases caused by a melanin-concentrating hormone.

Use of a compound represented by the formula:

• a compound represented by the formula:
• 313
• wherein R is hydrogen atom, a halogen atom or a cyclic group which may be substituted;
• X is a bond or a spacer having a main chain of 1 to 10 atoms;
• Yb is a spacer having a main chain of 1 to 6 atoms;
• ring A is benzene ring which may be further substituted;
• ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted;
• and
• R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
• or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring (except piperidine) which may be substituted;
• or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted;
• provided that Yb is not —CO—(C(Ra)H)na— (Ra is hydrogen atom or a hydrocarbon group which may be substituted, na is an integer of 1 to 10);
• or a salt thereof, for the manufacture of a pharmaceutical preparation for preventing or treating obesity.